P19-27. Willingness of adolescents in Soweto, South Africa to participate in future HIV prevention trials

N. Makongoza,J. Dietrich,K. Otwombek,G. de Bruyn,K. Sikkema,G. Gray

DOI: https://doi.org/10.1186/1742-4690-6-S3-P347

2009-10-22

Retrovirology

Abstract:

What problem does this paper attempt to address?

Discovery of novel nucleoside derivatives as selective lysine acetyltransferase p300 inhibitors for cancer therapy

Qiuzi Dai,Zigao Yuan,Qinsheng Sun,Zhuolin Ao,Binsheng He,Yuyang Jiang

DOI: https://doi.org/10.1016/j.bmcl.2024.129742

IF: 2.94

2024-04-11

Bioorganic & Medicinal Chemistry Letters

Abstract:P300 and CBP are two closely related histone acetyltransferases that are important transcriptional coactivators of many cellular processes. Inhibition of the transcriptional regulator p300/CBP is a promising therapeutic approach in oncology. However, there are no reported single selective p300 or CBP inhibitors to date. In this study, we designed and optimized a series of lysine acetyltransferase p300 selective inhibitors bearing a nucleoside scaffold. Most compounds showed excellent inhibitory activity against p300 with IC 50 ranging from 0.18 to 9.90 μM, except for J16, J29, J40, and J48. None of the compounds showed inhibitory activity against CBP (inhibition rate < 50 % at 10 μM). Then the cytotoxicity of the compounds against a series of cancer cells were evaluated. Compounds J31 and J32 showed excellent proliferation inhibitory activity on cancer cells T47D and H520 with desirable selectivity profile of p300 over CBP. These compounds could be promising lead compounds for the development of novel epigenetic inhibitors as antitumor agents.

chemistry, medicinal, organic
Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment

Panhong Gou,Wenchao Zhang

DOI: https://doi.org/10.1016/j.biopha.2024.116130

IF: 7.419

2024-01-13

Biomedicine & Pharmacotherapy

Abstract:CBP and p300 are homologous proteins exhibiting remarkable structural and functional similarity. Both proteins function as acetyltransferase and coactivator, underscoring their significant roles in cellular processes. The function of histone acetyltransferases is to facilitate the release of DNA from nucleosomes and act as transcriptional co-activators to promote gene transcription. Transcription factors recruit CBP/p300 by co-condensation and induce transcriptional bursting. Disruption of CBP or p300 functions is associated with different diseases, especially cancer, which can result from either loss of function or gain of function. CBP and p300 are multidomain proteins containing HAT (histone acetyltransferase) and BRD (bromodomain) domains, which perform acetyltransferase activity and maintenance of HAT signaling, respectively. Inhibitors targeting HAT and BRD have been explored for decades, and some BRD inhibitors have been evaluated in clinical trials for treating hematologic malignancies or advanced solid tumors. Here, we review the development and application of CBP/p300 inhibitors. Several inhibitors have been evaluated in vivo, exhibiting notable potency but limited selectivity. Exploring these inhibitors emphasizes the promise of targeting CBP and p300 with small molecules in cancer therapy.

pharmacology & pharmacy,medicine, research & experimental
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Loren M. Lasko,Clarissa G. Jakob,Rohinton P. Edalji,Wei Qiu,Debra Montgomery,Enrico L. Digiammarino,T. Matt Hansen,Roberto M. Risi,Robin Frey,Vlasios Manaves,Bailin Shaw,Mikkel Algire,Paul Hessler,Lloyd T. Lam,Tamar Uziel,Emily Faivre,Debra Ferguson,Fritz G. Buchanan,Ruth L. Martin,Maricel Torrent,Gary G. Chiang,Kannan Karukurichi,J. William Langston,Brian T. Weinert,Chunaram Choudhary,Peter de Vries,Arthur F. Kluge,Michael A. Patane,John H. Van Drie,Ce Wang,David McElligott,Ed Kesicki,Ronen Marmorstein,Chaohong Sun,Philip A. Cole,Saul H. Rosenberg,Michael R. Michaelides,Albert Lai,Kenneth D. Bromberg

DOI: https://doi.org/10.1038/nature24028

IF: 64.8

2017-09-27

Nature

Abstract:A potent and selective catalytic inhibitor of p300/CBP histone acetyltransferases suppresses tumour proliferation across multiple cell lineages, illustrating the therapeutic potential of drug-like small molecules that target histone acetyltransferases.

multidisciplinary sciences
Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.

Ruiqi Liu,Zhuqing Zhang,Hong Yang,Kaixin Zhou,Meiyu Geng,Weicheng Zhou,Mingming Zhang,Xun Huang,Yingxia Li

DOI: https://doi.org/10.1016/j.ejmech.2019.07.026

IF: 7.088

2019-01-01

European Journal of Medicinal Chemistry

Abstract:p300 is an important histone acetyltransferase in epigenetics, and its overexpression is closely related to various diseases such as cancers. C646 is one of the most representative p300 inhibitors and used in various studies of p300. However, its intrinsic drawbacks such as containing potentially toxic groups prevent it from further development. In order to find potent p300 inhibitors with good drug-like properties, C646 was chosen as the lead compound and a series of new p300 inhibitors were designed based on the principle of bioisosterism and reasonable scaffold hopping, and the structure-activity relationship was systematically explored. Ten of them were found to show comparable inhibitory activity as C646. The most potent compound, 1r (IC50 = 0.16 μM), showed better p300 inhibitory activity than C646 with improved drug-like properties. Western blotting experiment confirmed that 1r could reduce the level of H3K27 acetylation more significantly than C646. Further cellular assay indicated that it could inhibit the proliferation of human breast ductal carcinoma cell T47D and human breast cancer cell MCF7 with the IC50 values of 5.08 μM and 22.54 μM, respectively. Docking study of 1r with p300 protein showed the possible reasons for its higher inhibition activity. Thus, compound 1r might be with potential for development as a novel epigenetic agent targeting p300.
Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity

Jiankang Hu,Hongrui Xu,Tianbang Wu,Cheng Zhang,Hui Shen,Ruibo Dong,Qingqing Hu,Qiuping Xiang,Shuang Chai,Guolong Luo,Xiaoshan Chen,Yumin Huang,Xiaofan Zhao,Chao Peng,Xishan Wu,Bin Lin,Yan Zhang,Yong Xu

DOI: https://doi.org/10.1021/acs.jmedchem.3c02195

IF: 8.039

2024-04-24

Journal of Medicinal Chemistry

Abstract:The transcriptional coactivator cAMP response element binding protein (CREB)-binding protein (CBP) and its homologue p300 have emerged as attractive therapeutic targets for human cancers such as acute myeloid leukemia (AML). Herein, we report the design, synthesis, and biological evaluation of a series of cereblon (CRBN)-recruiting CBP/p300 proteolysis targeting chimeras (PROTACs) based on the inhibitor CCS1477. The representative compounds 14g (XYD190) and 14h (XYD198) potently inhibited the...

chemistry, medicinal
Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma

Qi Chang,Jiayi Li,Yue Deng,Ruilin Zhou,Bingwei Wang,Yujie Wang,Mingming Zhang,Xun Huang,Yingxia Li

DOI: https://doi.org/10.1021/acs.jmedchem.3c01468

IF: 8.039

2024-02-06

Journal of Medicinal Chemistry

Abstract:Adenoviral E1A binding protein 300 kDa (p300) and its closely related paralog CREB binding protein (CBP) are promising therapeutic targets for human cancer. Here, we report the first discovery of novel potent small-molecule PROTAC degraders of p300/CBP against hepatocellular carcinoma (HCC), one of the most common solid tumors. Based upon the clinical p300/CBP bromodomain inhibitor CCS1477, a conformational restriction strategy was used to optimize the linker to generate a series of PROTACs,...

chemistry, medicinal
Design, synthesis and biological evaluation of new RNF126-based p300/CBP degraders

Yan-Hua Lei,Qing Tang,Yang Ni,Cai-Hua Li,Peng Luo,Kun Huang,Xin Chen,Yong-Xia Zhu,Ning-Yu Wang

DOI: https://doi.org/10.1016/j.bioorg.2024.107427

Abstract:Histone acetyltransferase CREB-binding protein (CBP) and its homologous protein p300 are key transcriptional activators that can activate oncogene transcription, which present promising targets for cancer therapy. Here, we designed and synthesized a series of p300/CBP targeted low molecular weight PROTACs by assembling the covalent ligand of RNF126 E3 ubiquitin ligase and the bromodomain ligand of the p300/CBP. The optimal molecule A8 could effectively degrade p300 and CBP through the ubiquitin-proteasome system in time- and concentration-dependent manners, with half-maximal degradation (DC50) concentrations of 208.35/454.35 nM and 82.24/79.45 nM for p300/CBP in MV4-11 and Molm13 cell lines after 72 h of treatment. And the degradation of p300/CBP by A8 is dependent on the ubiquitin-proteasome pathway and its simultaneous interactions with the target proteins and RNF126. A8 exhibits good antiproliferative activity in a series of p300/CBP-dependent cancer cells. It could transcriptionally inhibit the expression of c-Myc, induce cell cycle arrest in the G0/G1 phase and apoptosis in MV4-11 cells. This study thus provided us a new chemotype for the development of drug-like PROTACs targeting p300/CBP, which is expected to be applied in cancer therapy.
Design, Synthesis, and Biological Evaluation of HDAC Degraders with CRBN E3 Ligase Ligands

Yingxin Lu,Danwen Sun,Donghuai Xiao,Yingying Shao,Mingbo Su,Yubo Zhou,Jia Li,Shulei Zhu,Wei Lu

DOI: https://doi.org/10.3390/molecules26237241

IF: 4.6

2021-11-29

Molecules

Abstract:Histone deacetylases (HDACs) play important roles in cell growth, cell differentiation, cell apoptosis, and many other cellular processes. The inhibition of different classes of HDACs has been shown to be closely related to the therapy of cancers and other diseases. In this study, a series of novel CRBN-recruiting HDAC PROTACs were designed and synthesized by linking hydroxamic acid and benzamide with lenalidomide, pomalidomide, and CC-220 through linkers of different lengths and types. One of these PROTACs, denoted 21a, with a new benzyl alcohol linker, exhibited comparably excellent HDAC inhibition activity on different HDAC classes, acceptable degradative activity, and even better in vitro anti-proliferative activities on the MM.1S cell line compared with SAHA. Moreover, we report for the first time the benzyl alcohol linker, which could also offer the potential to be used to develop more types of potent PROTACs for targeting more proteins of interest (POI).

chemistry, multidisciplinary,biochemistry & molecular biology
Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia

Tianbang Wu,Jiankang Hu,Xiaofan Zhao,Cheng Zhang,Ruibo Dong,Qingqing Hu,Hongrui Xu,Hui Shen,Xiaohan Zhang,Yan Zhang,Bin Lin,Xishan Wu,Qiuping Xiang,Yong Xu

DOI: https://doi.org/10.1021/acs.jmedchem.4c00335

IF: 8.039

2024-06-05

Journal of Medicinal Chemistry

Abstract:The epigenetic target CREB (cyclic-AMP responsive element binding protein) binding protein (CBP) and its homologue p300 were promising therapeutic targets for the treatment of acute myeloid leukemia (AML). Herein, we report the design, synthesis, and evaluation of a class of CBP/p300 PROTAC degraders based on our previously reported highly potent and selective CBP/p300 inhibitor 5. Among the compounds synthesized, 11c (XYD129) demonstrated high potency and formed a ternary complex between...

chemistry, medicinal
Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents

Qingjuan Chen,Binhui Yang,Xiaochen Liu,Xu D. Zhang,Lirong Zhang,Tao Liu

DOI: https://doi.org/10.7150/thno.73223

IF: 11.6

2022-01-01

Theranostics

Abstract:The histone acetyltransferases CBP and p300, often referred to as CBP/p300 due to their sequence homology and functional overlap and co-operation, are emerging as critical drivers of oncogenesis in the past several years. CBP/p300 induces histone H3 lysine 27 acetylation (H3K27ac) at target gene promoters, enhancers and super-enhancers, thereby activating gene transcription. While earlier studies indicate that CBP/p300 deletion/loss can promote tumorigenesis, CBP/p300 have more recently been shown to be over-expressed in cancer cells and drug-resistant cancer cells, activate oncogene transcription and induce cancer cell proliferation, survival, tumorigenesis, metastasis, immune evasion and drug-resistance. Small molecule CBP/p300 histone acetyltransferase inhibitors, bromodomain inhibitors, CBP/p300 and BET bromodomain dual inhibitors and p300 protein degraders have recently been discovered. The CBP/p300 inhibitors and degraders reduce H3K27ac, down-regulate oncogene transcription, induce cancer cell growth inhibition and cell death, activate immune response, overcome drug resistance and suppress tumor progression in vivo. In addition, CBP/p300 inhibitors enhance the anticancer efficacy of chemotherapy, radiotherapy and epigenetic anticancer agents, including BET bromodomain inhibitors; and the combination therapies exert substantial anticancer effects in mouse models of human cancers including drug-resistant cancers. Currently, two CBP/p300 inhibitors are under clinical evaluation in patients with advanced and drug-resistant solid tumors or hematological malignancies. In summary, CBP/p300 have recently been identified as critical tumorigenic drivers, and CBP/p300 inhibitors and protein degraders are emerging as promising novel anticancer agents for clinical translation.

medicine, research & experimental
Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response

Jason C Wong,Guozhi Tang,Xihan Wu,Chungen Liang,Zhenshan Zhang,Lei Guo,Zhenghong Peng,Weixing Zhang,Xianfeng Lin,Zhanguo Wang,Jianghua Mei,Junli Chen,Song Pan,Nan Zhang,Yongfu Liu,Mingwei Zhou,Lichun Feng,Weili Zhao,Shijie Li,Chao Zhang,Meifang Zhang,Yiping Rong,Tai-Guang Jin,Xiongwen Zhang,Shuang Ren,Ying Ji,Rong Zhao,Jin She,Yi Ren,Chunping Xu,Dawei Chen,Jie Cai,Song Shan,DeSi Pan,Zhiqiang Ning,XianPing Lu,Taiping Chen,Yun He,Li Chen

DOI: https://doi.org/10.1021/jm3011838

IF: 8.039

2012-01-01

Journal of Medicinal Chemistry

Abstract:Herein, we describe the pharmacokinetic optimization of a series of class-selective histone deacetylase (HDAC) inhibitors and the subsequent identification of candidate predictive biomarkers of hepatocellular carcinoma (HCC) tumor response for our clinical lead using patient-derived HCC tumor xenograft models. Through a combination of conformational constraint and scaffold hopping, we lowered the in vivo clearance (CL) and significantly improved the bioavailability (F) and exposure (AUC) of our HDAC inhibitors while maintaining selectivity toward the class I HDAC family with particular potency against HDAC1, resulting in clinical lead 5 (HDAC1 IC50 = 60 nM, mouse CL = 39 mL/min/kg, mouse F = 100%, mouse AUC after single oral dose at 10 mg/kg = 6316 h.ng/mL). We then evaluated 5 in a biomarker discovery pilot study using patient-derived tumor xenograft models, wherein two out of the three models responded to treatment. By comparing tumor response status to compound tumor exposure, induction of acetylated histone H3, candidate gene expression changes, and promoter DNA methylation status from all three models at various time points, we identified preliminary candidate response prediction biomarkers that warrant further validation in a larger cohort of patient-derived tumor models and through confirmatory functional studies.
Design, Synthesis and Biological Evaluation of (R)-5-methylpyrrolidin-2-ones As P300 Bromodomain Inhibitors with Anti-Tumor Activities in Multiple Tumor Lines.

Ruiqi Liu,Hong Yang,Zonglong Chen,Kaixin Zhou,Qiongyu Shi,Jiayi Li,Yuting Huang,Xun Huang,Yingxia Li

DOI: https://doi.org/10.1016/j.bioorg.2022.105803

IF: 5.307

2022-01-01

Bioorganic Chemistry

Abstract:p300/CBP bromodomain plays an important role in transcriptional regulation, and its overexpression is closely related to various diseases such as cancers. Two inhibitors of this target are currently in clinical trials but only CCS1477 (A1) have been published with the chemical structure. Herein, we modified the structure of CCS1477 based on the principle of bioisosterism and reasonable scaffold hopping, and discovered a series of new p300 bromodomain inhibitors with improved potency. More tumor cell lines sensitive to p300/CBP bromodomain inhibition were also identified. Among our new inhibitors, (R)-5-methylpyrrolidin-2-one derivitive B4 was the most potent one which showed comparable inhibitory activity against p300 (IC50 = 0.060 mu M) as lead A1 (IC50 = 0.064 mu M) at molecular level, and performed more potent proliferation inhibitory activities on various tumor cells than A1. Further we found that compound B4 had the high cell permeability and overcame the defect of the high efflux rate of A1, which could also explain the possible reason why B4 showed more potent inhibitory activities on sensitive tumor cells than lead A1. Western blotting analysis proved the target effects that B4 could suppress the expression of c-Myc and reduce H3K27 acetylation significantly. Liver microsomal metabolic stability assay and hERG channel inhibition evaluation illustrate compound B4 is metabolic stabilizable in human liver microsomes and has no hERG risk, which further demonstrate the good drug-likeness of B4. Therefore, compound B4 is a promising compound for further optimization and development.
Current development of CBP/p300 inhibitors in the last decade

Zhang-Xu He,Bing-Fei Wei,Xin Zhang,Yun-Peng Gong,Li-Ying Ma,Wen Zhao

DOI: https://doi.org/10.1016/j.ejmech.2020.112861

IF: 7.088

2021-01-01

European Journal of Medicinal Chemistry

Abstract:CBP/p300, functioning as histone acetyltransferases and transcriptional co-factors, represents an attractive target for various diseases, including malignant tumor. The development of small-molecule inhibitors targeting the bromodomain and HAT domains of CBP/p300 has aroused broad interests of medicinal chemist in expectation of providing new hope for anti-cancer treatment. In particular, the CBP/p300 bromodomain inhibitor CCS1477, identified by CellCentric, is currently undergone clinical evaluation for the treatment of haematological malignancies and prostate cancer. In this review, we depict the development of CBP/p300 inhibitors reported from 2010 to 2020 and particularly highlight their structure-activity relationships (SARs), binding modes, selectivity and pharmacological functions with the aim to facilitate rational design and development of CBP/p300 inhibitors.

chemistry, medicinal
Discovery of Novel Small Molecule HDAC1, 2, 3 Inhibitors -- Combined Receptor-Based and Ligand-Based Virtual Screening Strategy

Yi Wu,Bo Zhang,Xiaowu Dong,Shenglin Ma,Shengquan Hu

DOI: https://doi.org/10.2174/1570180819666211220124300

2022-01-01

Letters in Drug Design & Discovery

Abstract:Aims:This study aims to investigate and validate the potential drug target to HDAC1.Background:Human histone deacetylase 1 (HDAC1) can catalyze the deacetylation of histones belonging to the family of human histone deacetylases (HDACs). Amide hydrolase HDAC1 plays a key role in the development of many serious cancers such as prostate cancer, gastric cancer, lung cancer, esophageal cancer, colon cancer, and breast cancer. Therefore, HDAC1 inhibitors, promoting the transcription of a series of key genes such as the p53 gene and inhibiting the development of cancer through various downstream mechanisms, have great potential for the treatment of cancer.Objective:The objective of this study is to discover new skeleton HDAC1 inhibitors efficiently and conveniently with therapeutic potential for cancer.Method:Based on the crystal structure of HDAC1, through the combination of receptor-based and ligand- based virtual screening from the commercial compound library, the top-ranked compounds are selected for purchase through binding modes analysis, and their activities were verified through in vitro HDAC1 inhibitory biological experiments.Results:Based on LeDock, 5ICN showed good distinguishing ability and was used as the receptor. According to the results of the LeDock docking scoring from receptor-based virtual screening, 69 compounds with binding energy less than -7.5 kcal/mol were obtained and used for ligand-based virtual screening. A total of 21 novel compounds with high potential HDAC1 inhibitory activity were collected by combining the similarity searching (NN) and the multinomial Naive Bayes machine learning model (NB) methods. Through binding modes analysis, 10 compounds with different structures with potential HDAC1 inhibitory activity were selected and screened HDAC1 inhibitory in vitro. May267 showed moderate HDAC1 inhibitory activity, and the inhibition rate was 48% at a concentration of 20 μM.Conclusion:This study discovers novel small molecule HDAC1 inhibitors by combined receptor-based and ligand-based virtual screening strategy, which provides an efficient method for the discovery of other small molecule drugs. May267 shows moderate HDAC1 inhibitory activity, which can be further optimized as a lead compound. However, it still has the problem of poor kinase selectivity to be solved.
Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors

Bei-Er Jiang,Jiaxin Hu,Hao Liu,Zhitao Liu,Yu Wen,Mingyao Liu,Han-Kun Zhang,Xiufeng Pang,Li-Fang Yu

DOI: https://doi.org/10.1016/j.ejmech.2021.113893

IF: 7.088

2022-01-01

European Journal of Medicinal Chemistry

Abstract:The equilibrium between histone acetylation and deacetylation plays an important role in cancer initiation and progression. The histone deacetylases (HDACs) are a class of key regulators of gene expression that enzymatically remove an acetyl moiety from acetylated lysine ε-amino groups on histone tails. Therefore, HDAC inhibitors have recently emerged as a promising strategy for cancer therapy and several pan-HDAC inhibitors have globally been approved for clinical use. In the present study, we designed and synthesized a series of substituted indole-based hydroxamic acid derivatives that exhibited potent anti-proliferative activities in various tumor cell lines. Among the compounds tested, compound 4o, was found to be among the most potent in the inhibition of HDAC1 (half maximal inhibitory concentration, IC50 = 1.16 nM) and HDAC6 (IC50 = 2.30 nM). It also exhibited excellent in vitro anti-tumor proliferation activity. Additionally, compound 4o effectively increased the acetylation of histone H3 in a dose-dependent manner and inhibited cell proliferation by inducing cell cycle arrest and apoptosis. Moreover, compound 4o remarkably blocked colony formation in HCT116 cancer cells. Based on its favorable in vitro profile, compound 4o was further evaluated in an HCT116 xenograft mouse model, in which it demonstrated better in vivo efficacy than the clinically used HDAC inhibitor, suberanilohydroxamic acid. Interestingly, compound 4k was found to have a preference for the inhibition of HDAC6, with IC50 values of 115.20 and 5.29 nM against HDAC1 and HDAC6, respectively.

chemistry, medicinal
Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes

Jingjing Chen,Yalei Li,Jie Zhang,Minmin Zhang,Aihuan Wei,Hongchun Liu,Zhicheng Xie,Wenming Ren,Wenwen Duan,Zhuo Zhang,Aijun Shen,Youhong Hu

DOI: https://doi.org/10.1016/j.ejmech.2020.112868

IF: 7.088

2021-01-01

European Journal of Medicinal Chemistry

Abstract:According to the binding mode of ABBV-744 with bromodomains and the cape space of HDAC, the novel selective HDAC/BRD4 dual inhibitors were designed and synthesized by the pharmacophore fusion strategy. Evaluating the biomolecular activities through SARs exploration identified three kinds of selective dual inhibitors 41c (HDAC1/BRD4), 43a (pan-HDAC/BRD4) and 43d (HDAC6/BRD4(BD2)), whose target-related cellular activities in MV-4-11 cells were also confirmed. Significantly, the selective dual inhibitor 41c (HDAC1/BRD4) exhibited synergistic effects against MV-4-11 cells, which strongly induced G0/G1 cell cycle arrest and apoptosis, and the first HDAC6/BRD4(BD2) dual inhibitor was found. This study provides support for selective HDAC/BRD4 dual inhibitors as epigenetic probes based on pyrrolopyridone core for the future biological evaluation in different cancer cell lines.

chemistry, medicinal
Targeting p300/CBP Attenuates Hepatocellular Carcinoma Progression through Epigenetic Regulation of Metabolism

Ling-Yan Cai,Shi-Jie Chen,Sen-Hao Xiao,Qin-Juan Sun,Chen-Hong Ding,Bai-Nan Zheng,Xin-Yan Zhu,Shu-Qing Liu,Feng Yang,Ya-Xi Yang,Bing Zhou,Cheng Luo,Xin Zhang,Wei-Fen Xie

DOI: https://doi.org/10.1158/0008-5472.can-20-1323

IF: 11.2

2020-12-23

Cancer Research

Abstract:Targeting epigenetics in cancer has emerged as a promising anticancer strategy. p300/CBP is a central regulator of epigenetics and plays an important role in hepatocellular carcinoma (HCC) progression. Tumor-associated metabolic alterations contribute to the establishment and maintenance of the tumorigenic state. In this study, we used a novel p300 inhibitor, B029-2, to investigate the effect of targeting p300/CBP in HCC and tumor metabolism. p300/CBP-mediated acetylation of H3K18 and H3K27 increased in HCC tissues compared with surrounding noncancerous tissues. Conversely, treatment with B029-2 specifically decreased H3K18Ac and H3K27Ac and displayed significant antitumor effects in HCC cells in vitro and in vivo. Importantly, ATAC-seq and RNA-seq integrated analysis revealed that B029-2 disturbed metabolic reprogramming in HCC cells. Moreover, B029-2 decreased glycolytic function and nucleotide synthesis in Huh7 cells by reducing H3K18Ac and H3K27Ac levels at the promoter regions of amino acid metabolism and nucleotide synthesis enzyme genes, including PSPH, PSAT1, ALDH18A1, TALDO1, ATIC, and DTYMK. Overexpression of PSPH and DTYMK partially reversed the inhibitory effect of B029-2 on HCC cells. These findings suggested that p300/CBP epigenetically regulates the expression of glycolysis-related metabolic enzymes through modulation of histone acetylation in HCC and highlights the value of targeting the histone acetyltransferase activity of p300/CBP for HCC therapy. SIGNIFICANCE: This study demonstrates p300/CBP as a critical epigenetic regulator of glycolysis-related metabolic enzymes in HCC and identifies the p300/CBP inhibitor B029-2 as a potential therapeutic strategy in this disease.

oncology
Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors

Ying Xiong,Mingming Zhang,Yingxia Li

DOI: https://doi.org/10.2174/0929867326666190731141055

IF: 4.74

2020-10-08

Current Medicinal Chemistry

Abstract:CBP and p300 are two closely related Histone Acetyltransferases (HATs) that interact with numerous transcription factors and act to increase the expression of their target genes. Both proteins contain a bromodomain flanking the HAT catalytic domain that is important in binding of CBP/p300 to chromatin, which offers an opportunity to develop protein-protein interaction inhibitors. Since their discovery in 2006, CBP/p300 bromodomains have attracted much interest as promising new epigenetic targets for diverse human diseases, including inflammation, cancer, autoimmune disorders, and cardiovascular disease. Herein, we present a comprehensive review of the structure, function, and inhibitors of CBP/p300 bromodomains developed in the last several years, which is expected to be beneficial to relevant studies.

pharmacology & pharmacy,biochemistry & molecular biology,chemistry, medicinal
Discovery of selective HDAC6 inhibitors based on a multi-layer virtual screening strategy

Xingang Liu,Wenying Yan,Songsong Wang,Ming Lu,Hao Yang,Xu Chai,He Shi,Yang Zhang,Qingzhong Jia

DOI: https://doi.org/10.1016/j.compbiomed.2023.107036

IF: 7.7

2023-05-17

Computers in Biology and Medicine

Abstract:The abnormal enhancement of histone deacetylase 6 (HDAC6) has been demonstrated to be closely related to the occurrence and development of various malignant tumors, attracting extensive attention as a promising target for cancer therapy. Currently, only limited selective HDAC6 inhibitors have entered clinical trials, making the rapid discovery of selective HDAC6 inhibitors with safety profiles particularly urgent. In this study, a multi-layer virtual screening workflow was established, and the representative compounds screened were biologically evaluated in combination with enzyme inhibitory and anti-tumor cell proliferation experiments. The experimental results showed that the screened compounds L-25 , L-32 , L-45 and L-81 exhibited nanomolar inhibitory activity against HDAC6, and exerted a certain degree of anti-proliferative activities against tumor cells, especially the cytotoxicity of L-45 to A375 (IC 50 = 11.23 ± 1.27 μM) and the cytotoxicity of L-81 against HCT-116 (IC 50 = 12.25 ± 1.13 μM). Additionally, the molecular mechanisms underlying the subtype selective inhibitory activities of the selected compounds were further elucidated using computational approaches, and the hotspot residues on HDAC6 contributing to the ligands' binding were identified. In summary, this study established a multi-layer screening scheme to quickly and effectively screen out hit compounds with enzyme inhibitory activity and anti-tumor cell proliferation, providing novel scaffolds for the subsequent anti-tumor drug design based on HDAC6 target.

engineering, biomedical,computer science, interdisciplinary applications,mathematical & computational biology,biology
Discovery of Novel Benzimidazole Derivatives As Potent P300 Bromodomain Inhibitors with Anti-Proliferative Activity in Multiple Cancer Cells.

Zonglong Chen,Jiayi Li,Hong Yang,Yulong He,Qiongyu Shi,Qi Chang,Ruiqi Liu,Xun Huang,Yingxia Li

DOI: https://doi.org/10.1016/j.bmc.2022.116784

IF: 3.461

2022-01-01

Bioorganic & Medicinal Chemistry

Abstract:Adenovirus E1A-associated 300-kD protein (p300) bromodomain, which regulates gene expression by recognizing acetylated lysine (KAc) of histone, is a promising target for the treatment of cancer. Herein, a series of potent p300 bromodomain inhibitors with novel CBP30-based scaffolds was discovered through bioisosterism and conformational restriction strategies. The most promising compound 1u showed more potent inhibitory activity (IC50 = 49 nM) against p300 bromodomain and anti-proliferative activity in various cancer cell lines compared to CBP30. Moreover, 1u suppressed the expression of c-Myc and induced G1/G0 phase arrest and apoptosis in OPM-2 cells more potently than CBP30. This study provides new lead compounds for further research on the biological functions of p300.

P19-27. Willingness of adolescents in Soweto, South Africa to participate in future HIV prevention trials

Discovery of novel nucleoside derivatives as selective lysine acetyltransferase p300 inhibitors for cancer therapy

Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.

Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity

Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma

Design, synthesis and biological evaluation of new RNF126-based p300/CBP degraders

Design, Synthesis, and Biological Evaluation of HDAC Degraders with CRBN E3 Ligase Ligands

Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia

Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents

Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response

Design, Synthesis and Biological Evaluation of (R)-5-methylpyrrolidin-2-ones As P300 Bromodomain Inhibitors with Anti-Tumor Activities in Multiple Tumor Lines.

Current development of CBP/p300 inhibitors in the last decade

Discovery of Novel Small Molecule HDAC1, 2, 3 Inhibitors -- Combined Receptor-Based and Ligand-Based Virtual Screening Strategy

Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors

Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes

Targeting p300/CBP Attenuates Hepatocellular Carcinoma Progression through Epigenetic Regulation of Metabolism

Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors

Discovery of selective HDAC6 inhibitors based on a multi-layer virtual screening strategy

Discovery of Novel Benzimidazole Derivatives As Potent P300 Bromodomain Inhibitors with Anti-Proliferative Activity in Multiple Cancer Cells.